Trazodonum [Inn-Latin]
Brand names,
Trazodonum [Inn-Latin]
Analogs
Trazodonum [Inn-Latin]
Brand Names Mixture
Trazodonum [Inn-Latin]
Chemical_Formula
C19H22ClN5O
Trazodonum [Inn-Latin]
RX_link
http://www.rxlist.com/cgi/generic/traz.htm
Trazodonum [Inn-Latin]
fda sheet
Trazodonum [Inn-Latin]
msds (material safety sheet)
Trazodonum [Inn-Latin]
Synthesis Reference
Palazzo, Silvestrini, U.S. Pat 3,381,009 (1968)
Trazodonum [Inn-Latin]
Molecular Weight
371.864 g/mol
Trazodonum [Inn-Latin]
Melting Point
86-87 oC
Trazodonum [Inn-Latin]
H2O Solubility
Sparigly soluble
Trazodonum [Inn-Latin]
State
Solid
Trazodonum [Inn-Latin]
LogP
2.553
Trazodonum [Inn-Latin]
Dosage Forms
Tablet
Trazodonum [Inn-Latin]
Indication
For the treatment of depression.
Trazodonum [Inn-Latin]
Pharmacology
Trazodone is an antidepressant and hypnotic chemically unrelated to tricyclic, tetracyclic, or other known antidepressant agents. The mechanism of trazodone's antidepressant action in man is not fully understood. In animals, trazodone selectively inhibits serotonin uptake by brain synaptosomes and potentiates the behavioral changes induced by the serotonin precursor, 5-hydroxytryptophan. Cardiac conduction effects of trazodone in the anesthetized dog are qualitatively dissimilar and quantitatively less pronounced than those seen with tricyclic antidepressants. Trazodone is not a monoamine oxidase inhibitor and, unlike amphetamine-type drugs, does not stimulate the central nervous system. In man, trazodone is well absorbed after oral administration without selective localization in any tissue. Since the clearance of trazodone from the body is sufficiently variable, in some patients trazodone may accumulate in the plasma.
Trazodonum [Inn-Latin]
Absorption
Well absorbed following oral administration.
Trazodonum [Inn-Latin]
side effects and Toxicity
LD50=96mg/kg (i.v. in mice)
Trazodonum [Inn-Latin]
Patient Information
Trazodonum [Inn-Latin]
Organisms Affected
Humans and other mammals